Bridging Perspectives: How Canadian Patients and Caregivers View Quality of Life in Multiple Myeloma Compared to Validated Instruments《连接视角:加拿大患者与照护者对多发性骨髓瘤生活质量看法的比较研究及其与标准评估工具的验证》Current OncologyIF3.42026-04-050OAAI
The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature ReviewADVANCES IN THERAPYIF42021-11-1511OAAI
Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost-Utility AnalysisADVANCES IN THERAPYIF42021-10-265PREAI
Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysisBRITISH JOURNAL OF OPHTHALMOLOGYIF3.52021-01-049OAAI
COST-EFFECTIVENESS ANALYSIS OF EFINACONAZOLE FOR THE TREATMENT OF MILD TO MODERATE TOENAIL ONYCHOMYCOSIS IN CANADAVALUE IN HEALTHIF62019-05-010OAAI
LATANOPROSTENE BUNOD FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION: SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSISVALUE IN HEALTHIF62019-05-010OAAI
CANADIAN ECONOMIC IMPACT OF IMPROVED WORKPLACE PRODUCTIVITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VORTIOXETINEVALUE IN HEALTHIF62018-10-010OAAI
A GLOBAL ECONOMIC MODEL TO ASSESS THE COST EFFECTIVENESS OF NEW TREATMENTS FOR ADVANCED BREAST CANCER IN CANADAVALUE IN HEALTHIF62016-05-010OAAI
HOW TO CONDUCT ECONOMIC EVALUATIONS OF NEW TREATMENTS FOR ADVANCED CANCER WHEN OVERALL SURVIVAL DATA ARE NOT AVAILABLE? RESULTS FROM A SYSTEMATIC LITERATURE REVIEWVALUE IN HEALTHIF62015-11-010PREAI
DEVELOPMENT OF A GLOBAL ECONOMIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF TARGETED TREATMENTS USING COMPANION DIAGNOSTICS IN ADVANCED/METASTATIC CANCER TREATMENTVALUE IN HEALTHIF62014-11-010OAAI
VALIDATION OF A GLOBAL ECONOMIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF TARGETED TREATMENTS USING COMPANION DIAGNOSTICS IN ADVANCED/METASTATIC CANCER TREATMENT USING KRAS TESTING FOR CETUXIMAB THERAPY IN METASTATIC COLORECTAL CANCERVALUE IN HEALTHIF62014-11-011OAAI
COSTS OF ADVERSE EVENTS ASSOCIATED WITH TREATMENT OF HEPATITIS C VIRUS INFECTION: AN ANALYSIS USING THE QUEBEC PROVINCIAL DRUG REIMBURSEMENT PROGRAM DATABASEVALUE IN HEALTHIF62014-05-011OAAI
PARAMETER VALUES ASSOCIATED WITH THE DEVELOPMENT OF A GLOBAL ECONOMIC MODEL TO VALUE COMPANION DIAGNOSTICS IN ADVANCED/METASTATIC CANCER TREATMENTVALUE IN HEALTHIF62014-05-010OAAI
Cost-effectiveness of asenapine in the treatment of bipolar disorder in CanadaBMC PSYCHIATRYIF3.62014-01-2212OAAI
COST ASSOCIATED WITH ADVERSE EVENTS AND HEALTH CARE RESOURCES UTILIZATION IN HEPATITIS C VIRUS INFECTION IN QUEBEC, CANADAVALUE IN HEALTHIF62013-11-010OAAI
TRENDS IN HEALTH CARE RESOURCES UTILIZATION, COST AND MEDICATION SELECTION IN THE TREATMENT OF DIABETESVALUE IN HEALTHIF62013-11-010OAAI
The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in FranceEUROPEAN JOURNAL OF HEALTH ECONOMICSIF32013-08-0925OAAI
TREATMENT PATTERNS IN PEDIATRIC ANTIBIOTIC FORMULATIONS: AN ANALYSIS OF THE RAMQ DATABASEVALUE IN HEALTHIF62013-05-010OAAI